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1. INTRODUCTION
Each year millions of people from more than 180 countries gather 
to perform the annual Hajj pilgrimage in Makkah, Saudi Arabia. 
The Hajj season occurs at a fixed time each year from 8th to 13th 
day of the 12th month (Dhu al-Hijjah) in the Islamic calendar [1]. 
The Islamic/Lunar calendar is 11 days shorter than the Gregorian 
calendar [1]. This year the annual Hajj is expected to take place 
during August 8–13, 2019. The annual Hajj is one of the largest 
recurring mass gathering in the world and is the most studied 
mass gathering [1–8]. The number of pilgrims traveling to Saudi 
Arabia is based on the number of Muslims in each country and 
is calculated as one pilgrim per 1000 Muslims in the specific 
country [7]. The annual pilgrimage number had increased from 
58,584 in 1920 to 3,161,573 in 2012 and of those pilgrims in 2012 
about 1,752,932 were international pilgrims coming from outside 
Saudi Arabia [5]. The international pilgrims arrive to Saudi Arabia 
mainly by air and others may travel via land [4,8,9]. In previous 
years, there were occurrences of Hajj-related outbreaks [10–14] 
such as the 1987 international meningococcal disease outbreak 
caused by Neisseria meningitidis serogroup A [15–17], and sero-
group W135 [18], and the 2000–2001 N. meningitidis outbreak 
[14,15]. Thus, the annual Hajj requirements are updated annu-
ally in response to the occurrence of newly emerging infectious 
diseases such as Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV) [1,6,19] and the occurrence of international out-
breaks such as Ebola [7,8]. The recommended vaccinations for 
the Hajj are updated annually [6–9,20]. The 2019 required and 
recommended vaccinations were issued by the Saudi Ministry of 
Health [20]. Here, we summarize the 2019 Hajj mandatory and 
recommended vaccinations and discuss the possible impact of 
newly occurring outbreaks internationally, one of the most glob-
ally spread outbreaks is measles [21–23].
2.  MANDATORY AND RECOMMENDED 
VACCINATION FOR THE 2019 HAJJ
The recommended and mandatory vaccinations for pilgrims are 
summarized in Table 1. These vaccines include mandatory vac-
cinations (meningococcal vaccination, poliomyelitis vaccine, and 
yellow fever vaccine); recommended vaccination (influenza), and 
other immunization against vaccine-preventable diseases (diphthe-
ria, tetanus, pertussis, polio, measles and mumps).
2.1. Meningococcal Vaccination
The carriage rate of N. meningitidis was 3.4% arriving pilgrims [24]. 
The requirement of a bivalent A and C meningococcal vaccine for 
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A B S T R AC T
Each year millions of pilgrims perform the annual Hajj from more than 180 countries around the world. This is one of the 
largest mass gathering events and may result in the occurrence and spread of infectious diseases. As such, there are mandatory 
vaccinations for the pilgrims such as meningococcal vaccines. The 2019 annual Hajj will take place during August 8–13, 2019. 
Thus, we review the recommended and mandated vaccinations for the 2019 Hajj and Umrah. The mandatory vaccines required 
to secure the visa include the quadrivalent meningococcal vaccine for all pilgrims, while yellow fever, and poliomyelitis vaccines 
are required for pilgrims coming from countries endemic or with disease activity. The recommended vaccines are influenza, 
pneumococcal, in addition to full compliance with basic vaccines for all pilgrims against diphtheria, tetanus, pertussis, polio, 
measles, and mumps. It is imperative to continue surveillance for the spread of antimicrobial resistance and occurrence of all 
infectious diseases causing outbreaks across the globe in the last year, like Zika virus, MDR-Typhoid, Nipah, Ebola, cholera, 
chikungunya and Middle East Respiratory Syndrome Coronavirus.
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Table 1 | Required and recommended vaccination for the 2019 Hajj season 
Pilgrims coming from Vaccination
Yellow fever Africa:
Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African 
Republic, Chad, Congo, Côte d’Ivoire, Democratic Republic of  
the Congo, Equatorial Guinea, Ethiopia, Gabon, Guinea, Guinea- 
Bissau, Gambia, Ghana, Kenya, Liberia, Mali, Mauritania, Niger, 
Nigeria, Rwanda, Senegal, Sierra Leone, Sudan, South Sudan,  
Togo and Uganda
•   Yellow fever vaccination (≥10 days after the date  
of vaccination)
•   If no proof of vaccination, pilgrims will be placed 
under surveillance for 6 days from the last date of 
potential exposure
South and Central America:
Argentina, Venezuela, Brazil, Colombia, Ecuador, French Guiana, 





(a)  Any visitor (a)  Vaccination with ACYW135: vaccine within the 
last 3 years (polysaccharide vaccines); within  
5 years (conjugate vaccines), and >10 days before 
arriving Saudi Arabia
(b)  Visitors from African meningitis belt: Benin, Burkina Faso,  
Cameroon, Chad, Central African Republic, Côte d’Ivoire, 
Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Mali, Niger, 
Nigeria, Senegal and Sudan
(b)  ACYW135 vaccine (as above)
(c)  Pilgrims from within Saudi and the Hajj workers: all citizens and 
residents of Medina and Makkah
(c)  ACYW135 vaccine (as above)
Poliomyelitis (a)  Pilgrims from areas with active poliovirus transmission of a wild or 
vaccine-derived poliovirus: Afghanistan, Nigeria and Pakistan
(a)  At least one dose of bivalent oral polio vaccine 
(bOPV), or inactivated poliovirus vaccine (IPV), 
in the last 12 months and ≥ 4 weeks prior to 
departure
(b)  Countries at risk of polio reintroduction: Cameroon, Central  
African Republic, Chad, Guinea, Laos People’s Democratic  
Republic, Madagascar, Myanmar, Niger, and Ukraine
(b)  As above
(c)  Countries which remain vulnerable to Polio: Afghanistan, Nigeria, 
Pakistan, Papua New Guinea, Syria, Myanmar, Yemen and Somalia
(c)  As above and additionally those pilgrims will 
receive 1 dose of OPV on arrival to Saudi Arabia
Seasonal influenza All pilgrims (internal and international) and all health-care workers in 
the Hajj area
A recommendation
Cholera No specific vaccine requirement
pilgrims came in effect in 1987 after the occurrence of meningo-
coccal outbreaks [8], and the quadrivalent (A,C,Y, W135) vaccine 
became a requirement May 2001 [25,26] after the occurrence of two 
meningococcal outbreaks with serogroup W135 in 2000 and 2001 
[27–29]. Subsequent to the introduction of the meningococcal vac-
cination during the Hajj, the mean numbers of cases per year of 
Hajj-related invasive meningococcal disease decreased from 13 in 
1995 to 2 cases in 2011 [26]. A meningococcal vaccine is required 
for all pilgrims and specifically a conjugate vaccine is required for 
healthcare workers working at the Hajj. In a previous study, 97-100% 
of international pilgrims had the recommended meningococcal 
vaccination with the quadrivalent vaccine [24]. In recent years, N. 
meningitidis serogroup B vaccine became available [30] and a study 
showed that the majority of 3.4% of pilgrims with N. meningitidis 
carriage were due to serogroup B [24]. However, it was felt that this 
vaccine is not required due to insufficient data from the Hajj [24]. 
In previous years, ciprofloxacin (500 mg tablets) was administered 
as an oral chemoprophylaxis to pilgrims arriving from the African 
meningitis belt [6,8,15,31,32]. These recommendations were based 
on studies showing the carriage rate of N. meningitidis of 3.6% and 
1.4% in a paired cohort of pilgrims from high endemic countries at 
arrival and departure, respectively [24]. However, the role of cipro-
floxacin in eradicating the carrier sates of N. meningitidis showed a 
rate of 5.2% before and 4.6% after the Hajj following a single dose 
of ciprofloxacin (p = 0.65) [33]. The carriage rate of N. meningitidis 
among returning pilgrims varies from 0% to 0.6% [33–36]. Thus, 
ciprofloxacin was not adopted as a strategy post-Hajj and the cur-
rent recommendations from the Ministry of Health in Saudi Arabia 
reserve the option to administer prophylactic antibiotics to some 
travelers at the points of entry if deemed necessary [20].
2.2. Poliomyelitis
Although poliomyelitis is a vaccine preventable disease, its erad-
ication is delayed by the potential spread by international trav-
elers [37]. The number of poliomyelitis in 2018 and 2019 across 
many countries is shown in Figure 1, data were based on the Polio 
Global Eradication Initiative [38]. According to the World Health 
Organization, Saudi Arabia had been poliomyelitis free since 
October, 1995 [39]. However, a case was reported on January 24, 
1998, and the virus was closely related to a strain in Afghanistan/
Pakistan, and another case in 2004 was in a Sudanese child [39]. 
Based on a mathematical model, there is a possibility of 21 impor-
tations of poliovirus into Saudi Arabia via Hajj pilgrims [40]. Of 
the total 1,722,372 pilgrims in 2017, 25% were from polio priority 
countries [41]. It is also important to note that poliomyelitis is a 
disease of children <5 years old and the number of those among 
pilgrims is very small [42]. The Hajj requirement for people coming 
from polio priority countries is summarized in Table 1 and Figure 1. 
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Figure 1 | A world map showing countries where pilgrims are required to 
have poliomyelitis vaccination.
Figure 2 | A map showing the updated international travel and health lists 
of countries at risk of yellow fever.
Compliance with this requirement was 99.5% among pilgrims from 
at-risk countries: Pakistan, India, Nigeria, and Afghanistan [19].
2.3. Yellow Fever Vaccinations
Yellow fever vaccines are required by the International Health 
Regulations (IHR) for travelers from areas at risk of yellow fever 
transmission [43]. According to Annex 7 of the IHR in 2005, the 
WHO World Health Assembly approved lifelong protection of 
yellow fever vaccination and validity begins 10 days after the date of 
vaccination [44]. The updated international travel and health lists the 
following countries as at risk of yellow fever [45] is shown in Figure 2.
2.4. Influenza Vaccinations
The prevalence of the occurrence of influenza virus among pil-
grims varies depending on the study type and the diagnostic 
tool used with a range of 0–28.6% [36,46–62]. Influenza vaccine 
decreases development of influenza like-illness among pilgrims 
[63]. It is recommended that Hajj and Umrah pilgrims receive 
seasonal influenza vaccination [64]. However, influenza vaccine 
is currently not obligatory for pilgrims and thus compliance rate 
was 7.1–100% [63,65,66].
2.5. Pneumococcal Disease
There are limited data on the occurrence of pneumococcal disease 
among pilgrims. In a systematic review, the carriage of pneumo-
coccal vaccine serotype was higher in the post-Hajj period com-
pared with the pre-Hajj period [67] and the available data do not 
support a firm recommendation for the Streptococcus pneumoniae 
vaccination. However, it is known that 7–37% of pilgrims are older 
adults (>65 years old), and the compliance rate with S. pneumoniae 
vaccination is 5% among pilgrims [68].
2.6.  Newly Emerging and Re-emerging  
Infectious Diseases and the Risk 
during the Annual Hajj
The MERS-CoV was described only few weeks before the 2012 Hajj 
season and created a significant fear of the spread of this newly discov-
ered virus [47,56,69]. Multiple studies examined departing pilgrims 
with no evidence of MERS transmission [19,36,50,52,53,60,62, 
69–74]. However, there were few reports of MERS-CoV cases 
associated with the mini-Hajj, the Umrah [75,76]. Currently, 
pilgrims are advised to observe hand hygiene and follow cough 
etiquette and avoid contacts with camels [8]. This is also import-
ant to avoid the occurrence of diarrheal diseases. Few studies 
described the incidence and etiology of diarrhea among pilgrims 
[5]. In the past, cholera caused multiple outbreaks during the Hajj 
and the last ones were after the Hajj in 1984–86 and 1989 [42,77]. 
Contributing factors to the development of diarrheal disease are 
inadequate food hygiene, asymptomatic carriers of bacteria, and 
mass food preparation.
2.7. Measles and Rubella
There are multiple recent outbreaks of measles around the world. 
Since 2017, the number of measles cases increased 300% in the 
first 3 months of 2019 and multiple outbreaks in the United States 
[78–81]. There were reports of the occurrence of measles outbreak 
in relation to mass gathering events such as an international youth 
sporting event in USA resulting in cases in eight states [23], and 
the occurrence of measles among attendees of a church gathering 
and in the 2010 Taizé festival in France [21,22]. However, till date 
there is no reported outbreaks of measles during the Hajj. Few 
studies confirmed the occurrence of measles in relation to other 
mass gatherings and had been reported and recently reviewed [82]. 
The Saudi Ministry of Health strongly recommends that pilgrims 
update their immunization [1].
3. CONCLUSION AND COMMENTS
As usual, the Saudi Ministry of Health continues to observe the 
occurrence of any disease outbreaks around the world and issues 
recommendations for Hajj vaccinations and preventive measures 
[1,8]. There are mandated vaccines and additional recommended 
vaccines based on the available data and risk of spread of any disease. 
It is a cumulative experience from each Hajj and the dedication to 
provide a safe and healthy pilgrimage that draw on these guidelines 
and drive the annual planning for each Hajj [5,83,84].
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